Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Vous n'êtes pas connecté
Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Breathing in dirty air may do more than harm your lungs — it could also be making Alzheimer’s disease worse. A new study from the University of...
Breathing in dirty air may do more than harm your lungs — it could also be making Alzheimer’s disease worse. A new study from the University of...
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company...
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company...
Citryll, a biotech company pioneering a transformative approach to treating immune─mediated inflammatory diseases by targeting Neutrophil...
Citryll, a biotech company pioneering a transformative approach to treating immune─mediated inflammatory diseases by targeting Neutrophil...
Breathing polluted air may do more than harm the lungs and heart—it may also make Alzheimer’s disease worse. A new study has found that people...
Over the last few decades, researchers have learned more about the genetic and metabolic basis of Alzhet up to 80%. imer's disease and related...
TUESDAY, Sept. 9, 2025 -- Alzheimer disease (AD) is associated with greater neural flexibility (NF) in older adults, according to a study published...